Skip to main content
SpringerLink
Log in

Current Advances in the Psychopharmacology of Psychosomatic Medicine

  • Chapter
  • First Online:
Somatization and Psychosomatic Symptoms

  • 2134 Accesses

Abstract

Psychosomatic medicine is a way of approaching health problems, and psychosomatic disorders in general are pathological expression of biological, psychological, and socioecological parameters of human health.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Singh, A. N. (2006). Psychosomatic medicine and psychopharmacology, symbiosis of present future. International Congress Series, 1287, 12–16. Elsevier BV, Amsterdam.

    Article  Google Scholar 

  2. Singh, A. N. (2006). Recent advances in the psychopharmacology of psychosomatic medicine. International Congress Series, 1287, 206–212. Elsevier BV, Amsterdam.

    Article  Google Scholar 

  3. Singh, A. N., & Nagata, K. (2003). Recent advances in the psychopharmacology of psychosomatic medicine. Pyschiatria et Neurologia Japonica, 105, 441–447.

    Google Scholar 

  4. Singh, A. N. (1992). Pharmacological therapy in psychosomatic medicine. Japanese Journal of Psychosomatic Medicine, 32, 589–598.

    Google Scholar 

  5. Singh, A. N. (2010, September 10–12). Recent advances in the psychopharmacology of psychosomatic medicine. Paper presented at the 14th Congress of the Asian College of Psychosomatic Medicine, Beijing, China.

    Google Scholar 

  6. Boyer, W. (1995). Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis. International Clinical Psychopharmacology, 10, 45–49.

    Article  PubMed  Google Scholar 

  7. Bradwejn, J., Ahokas, A., Stein, D. J., et al. (2005). Venlafaxine extended release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. The British Journal of Psychiatry, 187, 352–359.

    Article  PubMed  Google Scholar 

  8. Sheehan, D. V., Raj, A. B., Sheehan, K. H., et al. (1990). Is buspirone effective for panic disorder? Journal of Clinical Psychopharmacology, 10, 3–11.

    Article  PubMed  Google Scholar 

  9. Simin, N. M., Hoge, E. A., Fischman, D., et al. (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. The Journal of Clinical Psychiatry, 67, 381–385.

    Article  Google Scholar 

  10. Sepede, G., de Berardis, D., Gambi, F., et al. (2006). Olanzapine augmentation in treatment-resistant panic disorder: A 12-week, fixed-dose, open-label trial. Journal of Clinical Psychopharmacology, 26, 45–49.

    Article  PubMed  Google Scholar 

  11. Keck, P. E., Jr., McElroy, S. L., Tugrul, K. C., et al. (1993). Anti-epileptic drugs for the treatment of panic disorder. Neuropsychobiology, 27, 150–153.

    Article  PubMed  Google Scholar 

  12. Sarchiapone, M., Amore, M., De Risio, S., et al. (2003). Mirtazapine in the treatment of panic disorder: An open-label trial. International Clinical Psychopharmacology, 18, 35–38.

    Article  PubMed  Google Scholar 

  13. Bertani, A., Perna, G., Migliarese, G., et al. (2004). Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study. Pharmacopsychiatry, 37, 206–210.

    Article  PubMed  Google Scholar 

  14. Singh, A. N. (1983). A clinical picture of benzodiazepine dependence and guidelines for reducing dependence (pp. 14–18). Princeton, NJ: Excerpta Medica Office.

    Google Scholar 

  15. Matthew, S. J., Amiel, J. M., Coplan, J. D., et al. (2005). Open-label trial of riluzole in generalized anxiety disorder. The American Journal of Psychiatry, 162, 2379–2381.

    Article  Google Scholar 

  16. Jefferson, J. W., & Greist, J. H. (1996). The pharmacotherapy of obsessive-compulsive disorder. Psychiatric Annals, 26, 202–209.

    Google Scholar 

  17. Silver, J. M., Sandberg, D. P., & Hales, R. E. (1990). New approaches in the pharmacotherapy of post-traumatic stress disorder. The Journal of Clinical Psychiatry, 51(Supp. 10), 33–38.

    Google Scholar 

  18. Lipper, S., Davidson, J. R., Grady, T. A., et al. (1986). Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics, 27, 849–854.

    Article  PubMed  Google Scholar 

  19. Fesler, F. A. (1991). Valproate in combat-related post-traumatic stress disorder. The Journal of Clinical Psychiatry, 52, 361–364.

    PubMed  Google Scholar 

  20. Baldwin, D., Bobes, J., Stein, D. J., et al. (1999). Paroxetine in social phobia/social anxiety disorder: Randomised, double-blind, placebo-controlled study. The British Journal of Psychiatry, 175, 120–126.

    Article  PubMed  Google Scholar 

  21. Baldwin, D., DeMartinis, N., Mallick, R. (2004, February 9–13). Patient-reported functioning in SAD and improvement with treatment: A comparison of venlafaxine XR, paroxetine and placebo. Program and abstracts of the International Congress of Biological Psychiatry, Sydney, Australia.

    Google Scholar 

  22. Stein, M. B., Fyer, A. J., Davidson, J. R., et al. (1999). Fluvoxamine treatment of social phobia: A double-blind, placebo-controlled study of fluvoxamine. 115, 128–134.

    Google Scholar 

  23. Van Ameringan, M. A., Lane, R. M., Walker, J. R., et al. (2001). Sertraline treatment of generalized social phobia: A 20 week, double-blind, placebo-controlled study. The American Journal of Psychiatry, 158, 275–281.

    Article  Google Scholar 

  24. Singh, A. N. (2006). Therapeutic uses of oriental approaches in psychosomatic medicine. International Congress Series, 1287, 91–96. Elsevier BV, Amsterdam.

    Article  Google Scholar 

  25. Singh, A. N. (1992). Non-pharmacological approaches of Hindu Buddhist medicine in psychosomatic disorders. Japanese Journal of Psychosomatic Medicine, 32, 417–425.

    Google Scholar 

  26. Singh, A. N., & Janier, A. K. (1999). Recent advances in the treatment of depression. Journal of the Indian Medical Association, 1, 19–24.

    Google Scholar 

  27. Perlis, R. H. (2007). Pharmacogenetic studies of antidepressant response: How far from the clinic? The Psychiatric Clinics of North America, 30, 125–138.

    Article  PubMed  Google Scholar 

  28. Smits, K. M., Smits, L. J., Schouten, J. S., et al. (2007). Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clinical Therapeutics, 29, 691–702.

    Article  PubMed  Google Scholar 

  29. Liu, Z., Zhu, F., Wang, G., et al. (2007). Association study of corticotrophin-releasing hormone receptor 1 gene polymorphisms and antidepressant response in major depressive disorder. Neuroscience Letters, 414(2), 155–158. Elsevier, Ireland.

    Article  PubMed  Google Scholar 

  30. Smits, K., Smits, L., Peeters, F., et al. (2007). Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. International Clinical Psychopharmacology, 22, 137–143.

    Article  PubMed  Google Scholar 

  31. Hu, X. Z., Rush, A. J., Charney, D., et al. (2007). Association between a functional serotonin transporter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of General Psychiatry, 64, 783–792.

    Article  PubMed  Google Scholar 

  32. Singh, A. N. (2004). Recent advances in the pharmacotherapy of insomnia. WHO Lecture Series, 6(1), 46–55.

    Google Scholar 

  33. Ikemi, Y. (1966). Integration of occidental and oriental psychosomatic treatment in integration of Eastern and Western psychosomatic medicine (pp. 37–46). Kyushu: Kyushu University Press.

    Google Scholar 

  34. Lieb, R., Meinschmidt, G., & Aryaya, R. (2007). Epidemiology of the association between somatoform disorders and anxiety and depressive disorders: An update. Psychosomatic Medicine, 69, 860–863.

    Article  PubMed  Google Scholar 

  35. Phillips, K. A., Albertini, R. S., & Rasmussen, S. A. (2002). A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Archives of General Psychiatry, 59, 381–388.

    Article  PubMed  Google Scholar 

  36. Fallon, B. A. (2004). Pharmacotherapy of somatoform disorders. Journal of Psychosomatic Research, 56, 455–460.

    Article  PubMed  Google Scholar 

  37. Mitchell, J. E., de Zwaan, M., & Roerig, J. L. (2003). Drug therapy for patients with eating disorders. Current Drug Targets. CNS and Neurological Disorders, 2(1), 17–29. Bentham Science Publishers, Oak Park, IL.

    Article  PubMed  Google Scholar 

  38. Yager, J. (2008). Binge eating disorder: The search for better treatments. The American Journal of Psychiatry, 165, 4–6.

    Article  PubMed  Google Scholar 

  39. Advokat, C., & Kutlesic, V. (1995). Pharmacotherapy of the eating disorders: A commentary. Neuroscience and Biobehavioural Reviews, 19(1), 59–66. Elsevier, USA.

    Article  Google Scholar 

  40. Nickel, C., Tritt, K., Muehlbacher, M., et al. (2005). Topiramate treatment in bulimia nervosa patients: A randomized, double-blind, placebo-controlled trial. International Journal of Eating Disorders, 38, 295–300.

    Article  PubMed  Google Scholar 

  41. Appolinario, J. C., Bacaltchuk, J., Sicheri, R., et al. (2003). A randomized double-blind placebo-controlled study of sibutramine in the treatment of binge eating disorder. Archives of General Psychiatry, 60, 1109–1116.

    Article  PubMed  Google Scholar 

  42. Silviera, R. O., Zanatto, V., Appolinario, J. C., et al. (2005). An open trial of reboxetine in obese patients with binge eating disorder. Eating and Weight Disorders, 10, e93–e96.

    Google Scholar 

  43. Snoeck, E., Peer, A., Mannens, G., et al. (1995). Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Journal of Biomedical Life Science - Psychopharmacology, 122, 223–229.

    Google Scholar 

  44. Percudani, M., Barbui, C., Fortino, I., et al. (2005). Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Journal of Clinical Psychopharmacology, 25, 468–470.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychopharmacology, Department of Psychiatry, Pharmacology and Neurosciences, Queen’s University, Kingston, ON, Canada

    Amarendra N. Singh M.D.

Authors
  1. Amarendra N. Singh M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amarendra N. Singh M.D. .

Editor information

Editors and Affiliations

  1. College of Medicine, Department of Psychiatry, Yonsei University, 50 Yonsei-ro, Seoul, 120-752, Korea, Republic of (South Korea)

    Kyung Bong Koh

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Singh, A.N. (2013). Current Advances in the Psychopharmacology of Psychosomatic Medicine. In: Koh, K. (eds) Somatization and Psychosomatic Symptoms. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7119-6_21

Download citation

Publish with us

Policies and ethics

Search

Navigation